Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.

Saved in:
Bibliographic Details
Title: Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.
Authors: Fabbri L; Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1368, Orsay, France. lucilla.fabbri@curie.fr.; Université Paris-Saclay, CNRS UMR3348, INSERM U1368, Orsay, France. lucilla.fabbri@curie.fr.; Equipe labellisée Ligue Nationale contre le Cancer, Orsay, France. lucilla.fabbri@curie.fr., Lagadec L; Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1368, Orsay, France.; Université Paris-Saclay, CNRS UMR3348, INSERM U1368, Orsay, France.; Equipe labellisée Ligue Nationale contre le Cancer, Orsay, France., Guérin E; Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1368, Orsay, France.; Université Paris-Saclay, CNRS UMR3348, INSERM U1368, Orsay, France.; Equipe labellisée Ligue Nationale contre le Cancer, Orsay, France., Lecourt H; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.; Université Paris-Sud, Université Paris-Saclay, Kremlin-Bicêtre, France.; Dermato-Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Baille D; Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1368, Orsay, France.; Université Paris-Saclay, CNRS UMR3348, INSERM U1368, Orsay, France.; Equipe labellisée Ligue Nationale contre le Cancer, Orsay, France., Besse L; Institut Curie, PSL University, CNRS UAR2016, Inserm US43, Université Paris-Saclay, Multimodal Imaging Center, Orsay, France., Messaoudi C; Institut Curie, PSL University, CNRS UAR2016, Inserm US43, Université Paris-Saclay, Multimodal Imaging Center, Orsay, France., Désaubry L; Center of Research in Biomedicine of Strasbourg, Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Strasbourg, France., Abou-Hamdan H; Center of Research in Biomedicine of Strasbourg, Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Strasbourg, France., Roy S; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.; Université Paris-Sud, Université Paris-Saclay, Kremlin-Bicêtre, France.; Dermato-Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Lombard B; Institut Curie, PSL University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France., Loew D; Institut Curie, PSL University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France., Scoazec JY; Institut Gustave Roussy, INSERM U1015, Bâtiment de Médecine Moléculaire 114 rue Edouard Vaillant, 94800, Villejuif, France., Robert C; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.; Université Paris-Sud, Université Paris-Saclay, Kremlin-Bicêtre, France.; Dermato-Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Vagner S; Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1368, Orsay, France. stephan.vagner@curie.fr.; Université Paris-Saclay, CNRS UMR3348, INSERM U1368, Orsay, France. stephan.vagner@curie.fr.; Equipe labellisée Ligue Nationale contre le Cancer, Orsay, France. stephan.vagner@curie.fr.
Source: EMBO molecular medicine [EMBO Mol Med] 2026 Jul 20. Date of Electronic Publication: 2026 Jul 20.
Publication Type: Journal Article
Journal Info: Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1757-4684
DOI:10.1038/s44321-026-00479-5